« Back
Home /
Idarubicin

Idarubicin

Item no.	HY-17381A-5mg
Manufacturer	MedChem Express
CASRN	58957-92-9
Amount	5 mg
Quantity options	100 mg 10 mg 1 ea 25 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	99.89
Citations	[1]Orlandi P, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17(6):663-7.\|[2]Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24(4):275-88.\|[3]Siegsmund MJ, et al. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31(3):365-70.\|[4]Gewirtz DA, et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41(5):361-\|[5]Kinnunen U, et al. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):301-3. Cancer Cell Int. 2024 Dec 26;24(1):430.\|Mol Carcinog. 2023 Jul 26.\|Anal Chem. 2022 Oct 4;94(39):13623-13630.\|bioRxiv. 2023 Jan 13.\|Cancer Lett. 2019 Oct 1;461:31-43. \|Exp Cell Res. 2020 Aug 1;393(1):112054.\|iScience. 2024 Jun 07.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|J Virol. 2019 May 15;93(11):e02230-18. \|Nat Cell Biol. 2024 Jul 22.\|Nat Commun. 2020 Apr 14;11(1):1792.\|Nucleic Acids Res. 2018 Apr 20;46(7):3284-3297.\|University of Paris. 2022 Sep 19.\|Viruses. 2020 Jun 10;12(6):628.
Smiles	OC(C(C(C1=CC=CC=C21)=O)=C3C2=O)=C4[C@H](C[C@@](C(C)=O)(O)CC4=C3O)O[C@@](O[C@@H](C)[C@H]5O)([H])C[C@@H]5N
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	4-Demethoxydaunorubicin
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	Antibiotic; Autophagy; Bacterial; c-Myc; DNA/RNA Synthesis; Fungal; Topoisomerase
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight	497.49
Product Description	Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts[1][2][3][4][5].
Manufacturer - Research Area	Cancer; Infection
Solubility	10 mM in DMSO
Manufacturer - Pathway	Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage
Isoform	Topo II
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question